BlackRock’s Braveheart Bio BRVE Stock Holding History

BlackRock’s Portfolio BRVE Stock Details BRVE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$20.3M	Buy	+1,007,129	New	+$26.5M	﹤0.01%	3218

Other funds holding BRVE

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Eventide Asset Management Boston, Massachusetts $7.14B AUM 65.02% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $296B AUM 23.14% 1-Year Est. Return

Pivotal bioVenture Partners Investment Advisor San Francisco, California $252M AUM 45.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

BlackRock's BRVE Position: Q3 2026 in Review

BlackRock opened a new position in Braveheart Bio (BRVE) in Q3 2026: 1,007,129 shares worth $20.3M. The stake represents ﹤0.01% of the portfolio and ranks #3218 among its holdings.

26 funds tracked by Wall St. Rank hold BRVE as of Q3 2026.

BlackRock held 1,007,129 shares of Braveheart Bio worth $20.3M as of Q3 2026.
Braveheart Bio was a new BlackRock position in Q3 2026.
Braveheart Bio made up ﹤0.01% of BlackRock's portfolio in Q3 2026, its #3218 holding.
26 funds tracked by Wall St. Rank held Braveheart Bio as of Q3 2026.

Based on BlackRock's 13F filing for Q3 2026, filed 13 Nov 2026.